Since activation of the ERK1/2 MAP kinases is a well-described downstream mediator of both GPCR and EGFR activity and is known to contribute significantly to human primary cancers and tumor-derived cell line carcinogenesis, we investigated the activity of ERK1/2, as a function of its phosphorylation, following agonism of FFA1 with AS2034178. Here, MAPK3 is linked to neoplasm.